Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 12/20 | 0.67 |
| ▸ | DDR2 | Q16832 | 3/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | BRAF | P15056 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15575243 | 0.92 | DDR2 (0.63) | RAF1DDR2L3MBTL1KMT2A | |
| SCHEMBL15574167 | 0.92 | DDR2 (0.62) | RAF1DDR2KMT2ASMN1; SMN2 | |
| SCHEMBL15574602 | 0.91 | RAF1 (0.78) | RAF1DDR2L3MBTL1BRAFKMT2A | |
| SCHEMBL16990638 | 0.91 | RAF1 (0.57) | RAF1DDR2L3MBTL1BRAFKMT2A | |
| SCHEMBL15575289 | 0.91 | DDR2 (0.65) | RAF1DDR2L3MBTL1BRAFKMT2A | |
| SCHEMBL16990618 | 0.90 | DDR2 (0.60) | RAF1DDR2BRAFKMT2A | |
| SCHEMBL16990585 | 0.89 | DDR2 (0.62) | RAF1DDR2KMT2A | |
| SCHEMBL16990712 | 0.89 | DDR2 (0.60) | RAF1DDR2L3MBTL1BRAF | |
| SCHEMBL16990683 | 0.89 | L3MBTL1 (0.62) | RAF1DDR2L3MBTL1KMT2ASMN1; SMN2 | |
| SCHEMBL16990661 | 0.89 | DDR2 (0.59) | RAF1DDR2BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | DDR2, DDR1, DDRGK1 | RAF1 3072/4885DDR2 1/4885L3MBTL1 3554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.